Related Experiment Video
Updated: Jul 16, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
1Cancer Chemotherapy Center, University of Occupational and Environmental Health, Japan.
Abstract:
Subsets of patients with non-small cell lung cancer respond remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib. In 2004, it was found that EGFR mutations occurring in the kinase domain are strongly associated with EGFR-TKI sensitivity. However, subsequent studies revealed that this relationship was not perfect and various predictive markers have been reported. These include EGFR gene copy numbers, status of ligands for EGFR, changes in other HER family genes or molecules downstream to EGFR including KRAS or AKT. In this review, we would like to review current knowledge of predictive factors for EGFR-TKI. As all but one phase III trials failed to show a survival advantage of the treatment arm involving EGFR-TKIs, it is necessary to select patients by these biomarkers in future clinical trials. Through these efforts, it would be possible to individualise EGFR-TKI treatment for patients suffering from lung cancer.
Insights
Certain non-small cell lung cancer patients benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Biomarkers beyond EGFR mutations are crucial for predicting TKI response and personalizing lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Non-small cell lung cancer (NSCLC) patients show variable responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
- EGFR mutations in the kinase domain were initially strong predictors of TKI sensitivity, but this association is not absolute.
- Other factors like EGFR gene copy number, ligand status, HER family alterations, and downstream signaling molecules (KRAS, AKT) also influence TKI efficacy.
Purpose of the Study:
- To review current knowledge on predictive biomarkers for EGFR-TKI treatment in NSCLC.
- To highlight the need for refined patient selection strategies in clinical trials.
- To emphasize the goal of individualizing EGFR-TKI therapy for lung cancer patients.
Main Methods:
- Literature review of studies investigating predictive markers for EGFR-TKI response.
- Analysis of clinical trial data and molecular profiling studies.
- Synthesis of current understanding of biomarkers influencing EGFR-TKI efficacy.
Main Results:
- EGFR mutations are important but not the sole determinant of EGFR-TKI response.
- Multiple biomarkers, including gene copy number and downstream signaling pathways, contribute to treatment outcomes.
- Phase III trials have largely failed to demonstrate overall survival benefits with EGFR-TKIs, underscoring the need for precise patient selection.
Conclusions:
- Accurate patient selection using a panel of biomarkers is essential for future EGFR-TKI clinical trials.
- Individualizing EGFR-TKI treatment based on predictive markers can optimize therapeutic outcomes for NSCLC patients.
- Further research into novel biomarkers and combination therapies is warranted to improve EGFR-TKI effectiveness.
